Table 4.

Current American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) recommendations for treatment regimen and duration with PrOD or PrO with or without ribavirin

Genotype/treatment history	Non-cirrhotic	Compensated cirrhosis
GT 1a; TN	PrOD + RBV for 12 weeks	PrOD + RBV for 24 weeks
GT 1a; TE	PrOD + RBV for 12 weeks	PrOD + RBV for 24 weeks
GT 1b; TN	PrOD for 12 weeks	PrOD for 12 weeks
GT 1b; TE	PrOD for 12 weeks	PrOD for 12 weeks
GT 4; TN	PrO + RBV for 12 weeks	Not recommended

Abbreviations: GT, genotype; PrOD, Paritaprevir/ritonavir-ombitasvir and dasabuvir; PrO, paritaprevir/ritonavir-ombitasvir; RBV, ribavirin; TE, treatment-experienced; TN, treatment-naïve.